2018–2019 Drug Updates in Hematologic Malignancies
Presented by Lauren Held, PharmD, BCOP
From Seattle Cancer Care Alliance, Seattle, Washington
Presenter’s disclosure of conflicts of interest is found at the end of this article.
J Adv Pract Oncol 2020;11(3):249–253 |
© 2020 Harborside™
Lauren Held, PharmD, BCOP, updated attendees on the FDA-approved therapies for initial or expanded indications for hematologic malignancies across the past year, as well as their supporting clinical trial data and best practices for safe and effective dosing and administration, drug monitoring, and adverse event management.
For access to the full length article, please sign in